Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
The Ministry of Health, Labor and Welfare (MHLW) handed out regulatory approvals for a slew of new medicines and indications on March 27, with four novel cancer therapies among them including Janssen Pharmaceutical’s (J&J) Lazcluze (lazertinib). Lazcluze, a third-generation oral…
To read the full story
Related Article
- Chuikyo OKs Listing of Tevimbra, Camzyos, Tremfya, and More
May 15, 2025
- Label Updated for Eliquis, Imbruvica, and Brimonidine: PMDA
March 31, 2025
- MHLW Flags Risk of Eye Disorders Associated with Tivdak upon Approval
March 31, 2025
- Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
- J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
REGULATORY
- 874 Defects or Health Damages Reported for Regenerative Medical Products in 1H FY2025
March 13, 2026
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
- GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
- Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
- Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…